Table 2.

Associations between IGF2R missense variants and breast cancer risk

SNP	Genotype	All
		Cases, n (%)	Controls, n (%)	OR (95% CI)*
rs8191746	CC	1584(99.5)	1862 (99.4)	1.00
	CT	8 (0.5)	11 (0.6)	0.76 (0.30–1.91)
rs8191754	CC	1096 (71.1)	1354 (71.2)	1.00
	CG/GG	445 (28.9)	547 (28.8)	1.14 (0.95–1.30)
rs6413491	GG	1568 (98.6)	1833 (98.4)	1.00
	GA/AA	23 (1.4)	29 (1.6)	0.85 (0.48–1.48)
IGF2R_C722T	CC	1572 (99.9)	1923 (100.0)	1.00
	CT	1 (0.06)	1 (0.1)	1.18 (0.07–18.97)
rs8191808	CC	1572 (99.1)	1846 (99.3)	1.00
	CG	14 (0.9)	14 (0.8)	1.28 (0.60–2.73)
rs8191844	CC	1562 (98.3)	1839 (98.6)	1.00
	CG/GG	27 (1.7)	26 (1.4)	1.12 (0.64–1.96)
IGF2R_C1194T	CC	1574 (97.9)	1851 (98.7)	1.00
	CT/TT	34 (2.1)	25 (1.3)	1.40 (0.82–2.39)
rs8191859	GG	1557 (98.9)	1877 (97.4)	1.00
	GA/AA	17 (1.1)	50 (2.6)	0.87 (0.48–1.59)
rs629849	AA	1283 (82.8)	1589 (83.7)	1.00
	AG/GG	267 (17.2)	309 (16.3)	1.06 (0.88–1.28)
IGF2R_C1822T	CC	1572 (98.7)	1839 (98.7)	1.00
	CT	21 (1.3)	24 (1.3)	0.92 (0.50–1.68)
rs8191904	GG	1551 (99.1)	1893 (98.4)	1.00
	GA/AA	14 (0.9)	31 (1.6)	0.54 (0.28–1.03)
rs8191955	CC	1550 (99.5)	1910 (99.5)	1.00
	CT	8 (0.5)	9 (0.5)	1.50 (0.55–4.14)

^*Adjusted for age and racial/ethnic group.